Puma Biotechnology | PBYI - Operating Expenses


Puma Biotechnology reported $49.26M in Operating Expenses for its fiscal quarter ending in June of 2024.





Operating Expenses Change Date
Agios Pharmaceuticals USD 130.77M 10.77M Mar/2026
Alnylam Pharmaceuticals USD 1.06B 160.97M Jun/2026
Amgen USD 11.69B 6.9B Jun/2026
Biogen USD 2.98B 1.02B Jun/2026
BioMarin Pharmaceutical USD 6.32B 5.69B Jun/2026
Daiichi Sankyo JPY 489.64B 21.08B Jun/2026
Exelixis USD 380.28M 20.8M Jun/2026
Gilead Sciences USD 3.95B 19.57B Jun/2026
Glaxosmithkline GBP 5.34B 3.83B Mar/2026
Incyte USD 973.64M 4.65B Jun/2026
MacroGenics USD 42.87M 21.68M Jun/2026
Moderna USD 960M 817M Jun/2026
Novartis USD 10.2B 912M Jun/2026
Pfizer USD 85.19B 4.91B Jun/2026
PTC Therapeutics USD 226.66M 19.64M Mar/2026
Puma Biotechnology USD 49.26M 3.2M Jun/2024
Regeneron Pharmaceuticals USD 31.71B 287.8M Jun/2026
Roche Holding CHF 18.9B 2.12B Jun/2026
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Sarepta Therapeutics USD 387.96M 15.59M Jun/2026
Takeda JPY 1.02T 89.68B Jun/2026
TG Therapeutics USD 218.66M 48.54M Jun/2026
Ultragenyx Pharmaceutical USD 289M 16M Jun/2026
Vanda Pharmaceuticals USD -1.14B 1.6B Dec/2025
Vertex Pharmaceuticals USD 2.07B 217.1M Jun/2026